This page is intended for healthcare professionals
Information about COVID-19 Vaccine Valneva
COVID-19 Vaccine (inactivated, adjuvanted) Valneva has been granted a marketing authorisation. It is indicated for active immunisation to prevent COVID-19 caused by SARS-CoV-2 in individuals 18 to 50 years of age.
Report a possible side effect for COVID-19 Vaccine
(inactivated, adjuvanted) Valneva
Healthcare professionals are asked to report any possible side effects via the national reporting system.